Can adagrasiib be used as the first choice after sotorasib resistance?

Answers from medical companions and pharmacists:

The world's first generic Lucius version of adagrasibu can be used as the first choice for sotorasib after drug resistance.

Sotorracib and adagrasib are both targeted drugs targeting KRAS G12C mutations in non-small cell lung cancer and other cancers. As the world's first generic, Lucius's version of adagrasib can be regarded as a potential alternative treatment option for patients who are resistant to sotoracib. The treatment also greatly reduces the economic burden on patients.

Analysis from Medical Companion Travel Pharmacist:

1. Introduction to Sotorasibu:

Sotorasibu is a specific, irreversible inhibitor of the GTPase protein KRAS G12C. It is clinically used to treat adult patients with KRAS G12C mutations and previously received at least one systemic therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC).

2. Introduction to adagrasib:

Adagrasib was developed by Mirati Therapeutics. It is a potent small molecule inhibitor of KRAS G12C mutated isoforms. It is used to treat metastatic or locally advanced non-small cell lung cancer. Patients have received at least one previous treatment and their tumors have abnormal KRAS G12C genes.

Adaglicib is an anti-tumor drug that works by interfering with the growth of cancer cells.

3. Use after drug resistance:

Like other targeted therapy drugs, patients may develop drug resistance. Facing the problem of sotorasib resistance, the new generation KRAS G12C inhibitor adagrasiib, with its unique molecular structure and pharmacological properties, is regarded as an important treatment option for patients after experiencing sotorasiib resistance.

Clinical studies have shown that adagrasiib can not only effectively inhibit KRAS G12C mutation, but also show clinical efficacy in some sotorasib-resistant cases, which is manifested in an improvement in disease control rate and a prolongation of progression-free survival.

Clinical basis:

A study demonstrated the application of adagrasib in advanced solid tumors carrying KRAS G12C mutations.

Based on 2-year follow-up data from Phase 1/1b dose expansion and dose escalation, adagrasiib monotherapy provided durable efficacy in patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Research results presented by Shirish M. Gadgeel, MD, at the 2023 World Conference on Lung Cancer showed that after a median follow-up of 26.9 months, the median overall survival (OS) of patients (n=132) was 14.1 months, with a 1-year OS rate of 52.8% and a 2-year OS rate of 31.3%. The evaluable median progression-free survival (PFS) among 128 patients was 6.9 months, with a 1-year PFS rate of 35.0% and a 2-year PFS rate of 13.9%. The disease control rate was 80%, 43% of patients experienced objective response, and the median duration of response (DOR) was 12.4 months.

Adagrasiib demonstrated durable clinical benefit and no new safety signals.

The price and purchase channels of Lucius version of adagrasib:

The price of Lucius version of adagrasib

A box of Lucius version of adagrasib generic medicine is priced at around 4050$-4150$.

Adagrasib was developed by the American company MIRATITHERAPS. It is a new drug for the treatment of KRAS G12C mutated non-small cell lung cancer. It was approved by the US FDA in November 2022. Its efficacy against KRAS G12C-mutated non-small cell lung cancer (NSCLC) is significant.

However, the original drug of adagrasib is expensive, and the monthly treatment cost is as high as more than 200,000 yuan. Many patients give up treatment because they cannot bear the cost of treatment.

At present, through continuous efforts and research, Laos Lucius Pharmaceutical Factory has successfully developed a replica of Adagrasibu tablets and launched it for sale in the global market. It is understood that the price of the generic version of adagrasibu is only one-tenth of the original drug, bringing new hope to patients.

How to purchase Lucius version of adagrasiib generic drugs

1. Purchase through hospitals and pharmacies in Laos: Patients can directly go to hospitals and designated pharmacies in Laos to purchase Lucius version of adagrasib generic drugs.

2. Domestic and overseas medical service institutions: There are currently some professional overseas medical service institutions in China. Patients can assist in purchasing through domestic qualified overseas medical service institutions. These institutions usually have cooperative relationships with pharmaceutical companies or hospitals in Laos and other countries and can assist with drug purchase and transportation procedures.

3. Online consultation and purchase: Some medical institutions or service platforms provide online consultation services. After receiving professional guidance, patients can order Lucius version of Adagrasib through legal and compliant channels, and have it delivered to their homes via international express delivery.

4. International cooperation projects: Under certain circumstances, some hospitals or research institutions may participate in international cooperation projects to provide eligible patients with the opportunity to obtain overseas drugs.

It should be noted that when purchasing Lucius version of generic adagrasib, patients should purchase it through formal channels to ensure drug quality. After purchasing the drug, you should strictly follow the doctor's instructions for treatment. The medication principles of the generic version of adagrasibu are the same as those of the original drug. At the same time, pay attention to the correct storage of adagrasibu and the shelf life of the drug.

Related hot article recommendations: